Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year ...

Liquidia › Biotech Liquidia (NASDAQ: LQDA) had good news to report about its latest commercialized product as the trading ...

Patients with SARD-ILD-PPF who continued nintedanib for 12 months or longer had better outcomes than those who discontinued therapy.

Global pulmonary function testing market growth is driven by rising prevalence of chronic respiratory diseases, increasing geriatric population, and growing adoption of diagnostic monitoring ...

Estimated YUTREPIA net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025Received more than 2,800 unique patient prescriptions since launch in Jun ...

Investing.com -- Insmed Incorporated (NASDAQ:INSM) stock rose 8% Friday morning following the company’s announcement of ...

Liquidia reported strong patient adoption since YUTREPIA’s launch in June 2025, receiving more than 2,800 unique patient prescriptions through December. The company has started treatment for more than ...

The data illustrate that several patients remained on zenocutuzumab well beyond progression, including multiple patients who continued treatment for more than one- or two-years post-progression.

Strip away the business cases and market opportunities, and here's what matters: 454 million people are suffering [1]. Most ...

Insmed Incorporated (NASDAQ:INSM) saw its shares surge about 8% on Friday morning after reporting strong preliminary revenue ...

A few years ago, I had a patient who affectionately went by the name “Pops.” At 85 years young, he was full of life and juggling multiple health issues alongside prostate cancer, yet determined not to ...